CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer

Anticancer Res. 2018 Jan;38(1):465-469. doi: 10.21873/anticanres.12245.

Abstract

Aim: The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the measurement of biomarkers is performed within 6 months after surgery.

Patients and methods: Four hundred and seventy-two patients with breast cancer were evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after surgery. Disease recurrence was recorded between 7-12 months after surgery. Disease recurrence occurred in 60 patients, while 412 patients remained in recurrence-free status.

Results: TPS levels of the recurrence group differed statistically significantly in the first and sixth month after surgery compared to recurrence-free group (p=0.0339, AUC=0.6056; p<0.0001, AUC=0.7196). CEA and CA 15-3 measurements did not achieve a statistically significant difference for any month examined.

Conclusion: TPS level in the sixth month after surgery is the best candidate biomarker to predict disease recurrence.

Keywords: Breast cancer; CA15-3; CEA; TPS; monitoring; surgery.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / surgery*
  • Carcinoembryonic Antigen / metabolism*
  • Female
  • Humans
  • Mastectomy, Radical
  • Middle Aged
  • Mucin-1 / metabolism*
  • Neoplasm Recurrence, Local / diagnosis*
  • Peptides / metabolism*

Substances

  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Mucin-1
  • Peptides
  • tissue polypeptide specific antigen